Bio-Path Holdings, Inc. BPTH
0.00 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.21 +0.21 +71,300.00%
After hours · Nov 9, 4:00 PM ET
0.0001 Day range 0.0001
0.0001 52-week range 0.0999
- YTD
- -99.50%
- 1 year
- -99.66%
News
defenseworld.net Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) Turn Therapeutics (NASDAQ: TTRX - Get Free Report) and Bio-Path (NASDAQ: BPTH - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will compare the…
defenseworld.net Critical Analysis: Amarillo Biosciences (OTCMKTS:AMAR) vs. Bio-Path (NASDAQ:BPTH) Institutional and Insider Ownership 5.7% of Bio-Path shares are held by institutional investors. 34.4% of Amarillo Biosciences shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are…
newsfilecorp.com Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path…
globenewswire.com Bio-Path Holdings Provides Clinical and Operational Update Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential…
globenewswire.com Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a…
globenewswire.com Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells
globenewswire.com Bio-Path Holdings Reports Full Year 2024 Financial Results HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a…
globenewswire.com Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models Recent…
benzinga.com US Stocks Mixed; NY State Business Activity Rises In February 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
globenewswire.com Bio-Path Holdings Provides Key Clinical Updates First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease
globenewswire.com Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia Study Progresses to Fourth Higher 90 mg/m 2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12,…
globenewswire.com Bio-Path Holdings Provides 2025 Clinical and Operational Update Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path…
benzinga.com US Stocks Higher, Micron Reports Downbeat Sales 
globenewswire.com Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic…
newsfilecorp.com Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q3 2024. To…
globenewswire.com Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance
zacks.com All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Bio-Path (BPTH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a…
seekingalpha.com Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Will O'Connor - Managing Director & Team Lead, Stern Investor Relations Peter…
globenewswire.com Bio-Path Holdings Reports Third Quarter 2024 Financial Results Expands DNAbilize ® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a…
globenewswire.com Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024 HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a…
globenewswire.com Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Nasdaq Surges Over 1%; DocuSign Shares Spike Higher
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Crude Oil Falls Over 4%; US Trade Deficit Narrows In August 
benzinga.com US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga.com Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - benzinga.com Market-Moving News for April 18th BPTH: 98% | Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Earnings Scheduled For November 15, 2023 Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is likely to report earnings for its third quarter. • Movano (NASDAQ:MOVE) is projected to report earnings for its third…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court…
- benzinga.com Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc.
- benzinga.com Why Comtech Telecommunications Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket Gainers Oblong, Inc. (NASDAQ: OBLG) shares rose 295.7% to $1.16 in pre-market trading.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Earnings Scheduled For August 15, 2023 Companies Reporting Before The Bell • Mainz Biomed (NASDAQ:MYNZ) is projected to report earnings for its second quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 92 stocks hit new 52-week lows.
- benzinga.com Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares jumped 75% to $9.60.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday saw 59 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 56 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 70 companies achieved new lows for the year.